Compare Gilead Sciences, Inc. (GILD) vs United States Oil ETF (USO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs United States Oil ETF — how do they compare? Gilead Sciences, Inc. trades at $135.66 (market cap $163.51B), while United States Oil ETF trades at $119.11. The key difference: Gilead Sciences, Inc. pays a 2.49% dividend while United States Oil ETF pays none. Which is the better fit depends on your goals.
| GILD | USO | |
|---|---|---|
Market Cap | $163.51B | — |
Sector | Health | — |
52-Week High | $155.80 | $152.96 |
52-Week Low | $108.22 | $66.17 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
USO trades at $119.30, down 0.72% on the day amid volatile oil market conditions. Technical indicators show a bullish overall signal with strong moving average support, though RSI levels suggest potential overbought conditions. Recent Middle East tensions have driven oil prices higher, with US-Iran conflicts creating supply disruption fears that benefit oil-focused investments.
The outlook remains bullish given ongoing geopolitical risks and supply constraints, though investors face volatility from potential conflict resolution or demand weakness. Key resistance sits at $121-$126, while support levels at $116-$119 provide downside protection in the current risk-on energy environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About United States Oil ETF
This ETF invests primarily in futures contracts for light, sweet crude oil, other types of crude oil, diesel-heating oil, gasoline, natural gas, and other petroleum-based fuels.
Read more on USO →
